PROFOUND MEDICAL CORP. (PROF) Operating Margin
- Operating margin · 12 months: Value -180.49%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -180.49% | Operating income / revenue. Period ending 2026-06-30. $-35.37M ÷ $19.60M × 100 ≈ -180.49% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -35.37M USD | Operating Income (Loss) |
| Revenue | 19.60M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 20.61M USD | Research and Development Expense |
| Selling, general and administration | 28.46M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-35.37M | $19.60M | (m) | $20.61M | $28.46M | -180.49% |
| 2026-03-31 | $-38.11M | $19.09M | (m) | $21.05M | $30.43M | -199.59% |
| 2025-12-31 | $-41.25M | $16.10M | (m) | $20.60M | $32.05M | -256.27% |
| 2025-09-30 | $-42.23M | $13.41M | (m) | $20.97M | $31.62M | -314.98% |
| 2025-06-30 | $-42.31M | $10.89M | (m) | $19.72M | $30.82M | -388.57% |
| 2025-03-31 | $-36.35M | $10.86M | (m) | $17.83M | $26.55M | -334.66% |
| 2024-12-31 | $-33.06M | $9.74M | (m) | $16.96M | $23.13M | -339.45% |
| 2024-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $-28.65M | $5.90M | (m) | $14.42M | $18.54M | -485.69% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| Lucid Diagnostics Inc. (LUCD) | United States | $0.170B | |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| KORU Medical Systems, Inc. (KRMD) | United States | $0.151B | -106.78 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |